Skip to content

Arbutus Biopharma

US · ABUS #3365 by market cap Listed 2015
4.13 -0.16 -3.76%
Live - 5344 symbols - heartbeat 81s ago · 2026-10-08 10:00
Pre-market 4.23 -1.40%
After-hours 4.30 +0.23%
Market cap
817.94M
P/B
3.16
EPS
-0.17
Reader sentiment Are you bullish or bearish on ABUS?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Earnings Flash (ABUS) Arbutus Biopharma Corporation Reports Q3 Revenue $529,000, Vs. FactSet Est of $1.3M
    MT Newswires · 2025/11/13
  • Rating change
    H.C. Wainwright Sticks to Its Buy Rating for Arbutus Biopharma (ABUS)
    TipRanks · 2023/4/25
  • Rating change
    Chardan Capital Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Raises Target Price to $5
    Market Newswire · 2024/11/20
  • Earnings Flash (ABUS) Arbutus Biopharma Posts 2025 Total Revenue $14.1M, Vs. FactSet Est of $13.6M
    MT Newswires · 2026/3/23
  • Rating change
    H.C. Wainwright Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $5
    Market Newswire · 2025/1/21
  • Rating change
    Chardan Capital Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $4
    Market Newswire · 2024/8/2
  • Rating change
    JMP Securities Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $5
    Market Newswire · 2025/3/31
  • ABUS Stock Has Given up Its Prior Gain. Arbutus Biopharma Shares Were Trading Higher After the Company Presented Clinical Trial Data From Its Two HBV Assets.
    Benzinga · 2025/5/7
  • Rating change
    H.C. Wainwright Sticks to Their Buy Rating for Arbutus Biopharma (ABUS)
    TipRanks · 2023/8/4
  • Rating change
    Robert W. Baird Remains a Hold on Arbutus Biopharma (ABUS)
    TipRanks · 2023/8/8
  • Rating change
    Jefferies Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Raises Target Price to $7
    Market Newswire · 2024/9/6
  • Earnings Flash (ABUS) Arbutus Biopharma Posts 2025 Loss $0.17 a Share, Vs. FactSet Est of $0.19 Loss
    MT Newswires · 2026/3/23
  • Rating change
    Chardan Capital Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Raises Target Price to $4.5
    Market Newswire · 2024/11/7
  • Rating change
    JMP Securities Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Raises Target Price to $5
    Market Newswire · 2024/8/2
  • Rating change
    H.C. Wainwright Keeps Their Buy Rating on Arbutus Biopharma (ABUS)
    TipRanks · 2023/9/12
  • Rating change
    H.C. Wainwright Remains a Buy on Arbutus Biopharma (ABUS)
    TipRanks · 2022/12/14
  • Earnings Flash (ABUS) Arbutus Biopharma Posts Q1 EPS $0.87, Vs. FactSet Est of $0.03 Loss
    MT Newswires · 2026/5/13
  • Rating change
    Arbutus Biopharma (ABUS) Receives a Buy From H.C. Wainwright
    TipRanks · 2023/4/5

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 10:00:20 · For reference only, not investment advice and not tailored to your situation.